BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, announced that its strategic distribution and licensing agreement with Electrome Corporation has entered the execution phase, with manufacturing underway for the launch of its flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform. The partnership aims to accelerate awareness and adoption of drug-free pain relief technologies across North America.
Electrome is building an AI-native pain management platform that integrates artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. This system is designed to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions. Under the agreement, Electrome will market and distribute BioElectronics' FDA-cleared pulsed shortwave therapy products, including ActiPatch and other portfolio items.
Kelly Whelan, President of BioElectronics Corporation, stated, “We are excited to officially begin the commercial phase of this relationship with Electrome. The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth.”
Electrome’s planned rollout will focus on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems to streamline the purchasing experience and increase awareness of non-drug pain management solutions. Ken Mayer, CEO of Electrome Corporation, commented, “We believe BioElectronics’ technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption.”
BioElectronics’ pulsed shortwave therapy technology provides drug-free, non-invasive pain relief through a wearable platform cleared by the U.S. FDA for adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures. Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.
This partnership underscores the growing shift toward non-pharmaceutical pain management options, particularly as concerns over opioid addiction and side effects of traditional painkillers persist. The integration of AI-driven marketing and ecommerce could accelerate consumer adoption of drug-free alternatives, potentially impacting the broader pain management industry. For readers, this means increased access to FDA-cleared, non-invasive pain relief solutions that can be used at home, offering an alternative to medications or invasive procedures.
